Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for OptimizeRx (OPRX) over the last 13 years, with Q3 2025 value amounting to $8.6 million.

  • OptimizeRx's Cost of Revenue rose 876.37% to $8.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.0 million, marking a year-over-year increase of 1517.1%. This contributed to the annual value of $32.7 million for FY2024, which is 1441.9% up from last year.
  • According to the latest figures from Q3 2025, OptimizeRx's Cost of Revenue is $8.6 million, which was up 876.37% from $10.6 million recorded in Q2 2025.
  • In the past 5 years, OptimizeRx's Cost of Revenue ranged from a high of $10.6 million in Q2 2025 and a low of $5.0 million during Q2 2022
  • Over the past 5 years, OptimizeRx's median Cost of Revenue value was $7.1 million (recorded in 2024), while the average stood at $7.3 million.
  • Per our database at Business Quant, OptimizeRx's Cost of Revenue soared by 5746.38% in 2021 and then plummeted by 1962.45% in 2022.
  • Quarter analysis of 5 years shows OptimizeRx's Cost of Revenue stood at $7.9 million in 2021, then fell by 9.1% to $7.2 million in 2022, then surged by 46.22% to $10.5 million in 2023, then decreased by 2.23% to $10.3 million in 2024, then fell by 16.92% to $8.6 million in 2025.
  • Its Cost of Revenue stands at $8.6 million for Q3 2025, versus $10.6 million for Q2 2025 and $8.6 million for Q1 2025.